BioWorld

Dec. 1, 2005

InSite's Pink Eye Treatment Proves Positive In Phase III

PIramed In $230M Preclinical Cancer Deal With Genentech

VC Syndication Key For Young European Biotechnology Firms

Other News To Note

BioCryst Out-Licenses BCX-4208 To Roche In Potential $560M Deal

The holiday season is coming early to BioCryst Pharmaceuticals Inc., which could earn more than half a billion dollars per terms of a just-announced licensing deal with F. Hoffmann-La Roche Ltd. (BioWorld Today) Read More

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 12, 2025

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...